A Phase I Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor
activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of
patients with progressive mCRPC in dose-escalation phase